ACE and atrial fibrillation: It should be noted that previous studies failed to demonstrate a benefit of beta-adrenoceptor blockers and calcium channel blockers over other drug classes such as angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, and diuretics.30–32 The potential reduction in AF risk through alpha-adrenoceptor blockers and beta-adrenoceptor blockers is further supported by the ERADICATE-AF atrial, which shows that renal denervation in addition to catheter ablation is beneficial for long-term antiarrhythmic efficacy.